Association of interleukin‑6 (‑174 G/C) polymorphism with the prostate cancer risk: A meta‑analysis

Yang,Mingyuan; Li,Chao; Li,Ming

doi:10.3892/br.2014.300

Association of interleukin‑6 (‑174 G/C) polymorphism with the prostate cancer risk: A meta‑analysis

Authors:
- Mingyuan Yang
- Chao Li
- Ming Li
View Affiliations

Affiliations: Department of Orthopedics, Changhai Hospital, Second Military Medical University, Shanghai 200438, P.R. China
Published online on: June 16, 2014 https://doi.org/10.3892/br.2014.300
Pages: 637-643

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine whether the interleukin‑6 (IL‑6) (‑174 G/C) gene polymorphism correlates with prostate cancer. A meta‑analysis based on former studies was conducted and the results suggest that there was no significant association between IL‑6 (‑174 G/C) polymorphism and the prostate cancer risk. However, a recent study published in January 2014 showed that the GG genotype may be associated with an increased risk of prostate cancer in Caucasian subjects, whereas the CC genotype was associated with an increased risk in the African‑American subjects, which was inconsistent with former studies. Databases, including PubMed, Embase, Web of Science, the Cochrane Library, Chinese Biomedical Literature Database and Wanfang database, were searched between January 1994 and March 2014 to determine the eligible IL‑6 (‑174 G/C) polymorphism studies and the susceptibility of the prostate cancer risk. A total of 11 studies with 10,745 cases and 13,473 controls fulfilled the inclusion criteria subsequent to assessment by two investigators. The pooled odds ratio (OR) with 95% confidence interval (95% CI) was calculated to examine the associations, and subgroup analyses were performed according to the ethnicity. Overall, no significant association was found between the IL‑6 (‑174 G/C) polymorphism and prostate cancer risk, whereas the subgroup analysis suggested that the association between the IL‑6 (‑174 G/C) polymorphism and prostate cancer was slightly significant under the homozygote (CC vs. GG: OR, 3.43; 95% CI, 1.01‑11.71; P=0.049) and recessive models (CC vs. GG/GC: OR, 3.51; 95% CI, 1.04‑11.82; P=0.042) in African‑American patients. However, no significant association was found in the Caucasian, Asian or mixed populations under the five genetic models by stratifying studies for ethnicity. In conclusion, the present study suggested that there was no significant association between the IL‑6 (‑174 G/C) polymorphism and prostate cancer risk in Caucasian and Asian patients, whereas the CC genotype may be associated with an increased risk in the African‑American patients.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
2	Discacciati A and Wolk A: Lifestyle and dietary factors in prostate cancer prevention. Recent Results Cancer Res. 202:27–37. 2014. View Article : Google Scholar : PubMed/NCBI
3	Lai GY, Giovannucci EL, Pollak MN, et al: Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study. Cancer Causes Control. 25:625–632. 2014. View Article : Google Scholar : PubMed/NCBI
4	Wu J and Yu E: Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy. Cancer Metastasis Rev. Jan 12–2014.(Epub ahead of print).
5	McGregor SE, Courneya KS, Kopciuk KA, Tosevski C and Friedenreich CM: Case-control study of lifetime alcohol intake and prostate cancer risk. Cancer Causes Control. 24:451–461. 2013. View Article : Google Scholar : PubMed/NCBI
6	Rundle A, Jankowski M, Kryvenko ON, Tang D and Rybicki BA: Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate. Cancer Epidemiol Biomarkers Prev. 22:898–904. 2013. View Article : Google Scholar : PubMed/NCBI
7	Nelson WG, Demarzo AM and Yegnasubramanian S: The diet as a cause of human prostate cancer. Cancer Treat Res. 159:51–68. 2014. View Article : Google Scholar : PubMed/NCBI
8	Sfanos KS, Isaacs WB and DeMarzo AM: Infections and inflammation in prostate cancer. Am J Clin Exp Urol. 1:3–11. 2013.
9	Kwon OJ, Zhang L, Ittmann MM and Xin L: Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci USA. 111:E592–E600. 2014. View Article : Google Scholar : PubMed/NCBI
10	Boikos SA, Nirschl C, Martin A, Alme A, Harris T and Drake CG: Prostate cancer cells up-regulate PD-L1 in response to pro-inflammatory cytokines. Cancer Res. 73(Suppl 1): Abstract 1437. 2013. View Article : Google Scholar
11	Ianni M, Porcellini E, Carbone I, et al: Genetic factors regulating inflammation and DNA methylation associated with prostate cancer. Prostate Cancer Prostatic Dis. 16:56–61. 2013. View Article : Google Scholar : PubMed/NCBI
12	Miyake M, Lawton A, Goodison S, Urquidi V and Rosser CJ: Chemokine (C-X-C motif) ligand 1 (CXCL1) protein expression is increased in high-grade prostate cancer. Pathol Res Pract. 210:74–78. 2014. View Article : Google Scholar : PubMed/NCBI
13	Dakhova O, Rowley D and Ittmann M: Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression in vivo. Clin Cancer Res. 20:100–109. 2014. View Article : Google Scholar : PubMed/NCBI
14	Heber D: Cancer and inflammation. Immunonutrition: Interactions of Diet, Genetics, and Inflammation. Aggarwal BB and Heber D: CRC Press; Boca Raton, FL: 101. 2014, View Article : Google Scholar
15	Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G and Witte JS: COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer. 97:557–561. 2007. View Article : Google Scholar : PubMed/NCBI
16	Danforth KN, Hayes RB, Rodriguez C, et al: Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis. 29:568–572. 2008. View Article : Google Scholar : PubMed/NCBI
17	Shahedi K, Lindström S, Zheng SL, et al: Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer. 119:668–672. 2006. View Article : Google Scholar : PubMed/NCBI
18	Panguluri RC, Long LO, Chen W, et al: COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis. 25:961–966. 2004. View Article : Google Scholar : PubMed/NCBI
19	Woo JR, Liss MA, Muldong MT, et al: Tumor infiltrating B-cells are increased in prostate cancer tissue. J Transl Med. 12:302014. View Article : Google Scholar : PubMed/NCBI
20	Lv L, Yuan J, Huang T, et al: Stabilization of Snail by HIF-1α and TNF-α is required for hypoxia-induced invasion in prostate cancer PC3 cells. Mol Biol Rep. Mar 8–2014.(Epub ahead of print).
21	McDonald AC, Vira MA, Vidal AC, Gan W, Freedland SJ and Taioli E: Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001–2008. National Health and Nutrition examination survey. Prostate. 74:561–567. 2014.PubMed/NCBI
22	Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN and Stock RG: C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int. 95:961–962. 2005. View Article : Google Scholar
23	Aulisa L, Papaleo P, Pola E, et al: Association between IL-6 and MMP-3 gene polymorphisms and adolescent idiopathic scoliosis: a case-control study. Spine (Phila Pa 1976). 32:2700–2702. 2007. View Article : Google Scholar : PubMed/NCBI
24	Shibata N, Ohnuma T, Takahashi T, et al: Effect of IL-6 polymorphism on risk of Alzheimer disease: genotype-phenotype association study in Japanese cases. Am J Med Genet. 114:436–439. 2002. View Article : Google Scholar : PubMed/NCBI
25	Bader H: Clinical and systemic implications of periodontal disease susceptibility: the importance of IL-6 polymorphism. Dentistry. 4:1872014.
26	Yang Z, Liang Y, Qin B and Zhong R: A meta-analysis of the association of IL-6 -174 G/C and -572 G/C polymorphisms with systemic lupus erythematosus risk. Rheumatol Int. 34:199–205. 2014. View Article : Google Scholar : PubMed/NCBI
27	Zhang HY, Feng L, Wu H and Xie XD: The association of IL-6 and IL-6R gene polymorphisms with chronic periodontitis in a Chinese population. Oral Dis. 20:69–75. 2014. View Article : Google Scholar : PubMed/NCBI
28	Taniguchi K and Karin M: IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 26:54–74. 2014. View Article : Google Scholar : PubMed/NCBI
29	Yao X, Huang J, Zhong H, et al: Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 141:125–139. 2014. View Article : Google Scholar : PubMed/NCBI
30	Mandić S, Sudarević B, Marczi S, et al: Interleukin-6 polymorphism and prostate cancer risk in population of Eastern Croatia. Coll Antropol. 37:907–911. 2013.PubMed/NCBI
31	Pierce BL, Biggs ML, DeCambre M, et al: C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control. 20:1193–1203. 2009.PubMed/NCBI
32	Mandal S, Abebe F and Chaudhary J: -174G/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race. Genet Mol Res. 13:139–151. 2014. View Article : Google Scholar : PubMed/NCBI
33	Zhang J, Dhakal IB, Lang NP and Kadlubar FF: Polymorphisms in inflammatory genes, plasma antioxidants, and prostate cancer risk. Cancer Causes Control. 21:1437–1444. 2010. View Article : Google Scholar : PubMed/NCBI
34	Dossus L, Kaaks R, Canzian F, et al: PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis. 31:455–461. 2010. View Article : Google Scholar : PubMed/NCBI
35	Wang MH, Helzlsouer KJ, Smith MW, et al: Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate. 69:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
36	Moore SC, Leitzmann MF, Albanes D, et al: Adipokine genes and prostate cancer risk. Int J Cancer. 124:869–876. 2009. View Article : Google Scholar : PubMed/NCBI
37	Bao S, Yang W, Zhou S and Ye Z: Relationship between single nucleotide polymorphisms in -174G/C and -634C/G promoter region of interleukin-6 and prostate cancer. J Huazhong Univ Sci Technolog Med Sci. 28:693–696. 2008. View Article : Google Scholar : PubMed/NCBI
38	Kesarwani P, Ahirwar DK, Mandhani A and Mittal RD: Association between -174 G/C promoter polymorphism of the interleukin-6 gene and progression of prostate cancer in North Indian population. DNA Cell Biol. 27:505–510. 2008. View Article : Google Scholar : PubMed/NCBI
39	Michaud DS, Daugherty SE, Berndt SI, et al: Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res. 66:4525–4530. 2006. View Article : Google Scholar : PubMed/NCBI
40	Zabaleta J, Su LJ, Lin HY, et al: Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis. 30:1358–1362. 2009. View Article : Google Scholar : PubMed/NCBI
41	Magalhães JF, Cortinhas AF, Albuquerque CM, et al: Interleukin-6 gene -174G>C and -636G>C promoter polymorphisms and prostate cancer risk. Mol Biol Rep. 40:449–455. 2013.
42	Zhang H, Xu Y, Li L, Liu R and Ma B: The interleukin-6 -174G/C polymorphism and prostate cancer risk: a systematic review and meta-analysis. Urol Int. 88:447–453. 2012. View Article : Google Scholar : PubMed/NCBI